
UK Valproate Restrictions in Men Justified? New Data
As previously reported by Medscape Medical News , the decision to restrict the drug in women and in men younger than 55 years was made in January 2024, after the UK Medicines and Healthcare products Regulatory Agency issued new guidance on the drug's use.
'Paternal exposure to antiseizure medication in association with conception is unlikely to pose any major risk for the offspring,' the investigators led by Jakob Christensen, DrMedSci, consultant neurologist at Aarhus University Hospital and professor at Aarhus University, Aarhus, Denmark, noted.
The study was published online on May 22 in JAMA Network Open .
Unnecessary Precaution?
In the US and Europe, there is strong guidance about avoiding valproate in pregnant women and women of childbearing age due to an elevated risk for birth defects and other developmental problems.
In January 2024, the European Medicines Agency's (EMA's) safety committee (Pharmacovigilance Risk Assessment Committee [PRAC]) expanded precautionary measures on valproate use to men considering fatherhood. The advisory was fueled largely by an observational study by the contract research organization IQVIA.
The study showed that about 5 out of 100 children had an NDD when born to fathers taking valproate during the 3 months before conception compared with about 3 out of 100 when born to fathers treated with lamotrigine or levetiracetam.
Last summer, Christensen and colleagues were unable to replicate the IQVIA results in a study using a subset of the same IQVIA data. However, at the time, only limited information about the IQVIA study was publicly available.
Once additional information from the IQVIA study became available, the researchers tried again to replicate the findings, aligning their methods more closely with the IQVIA study.
Despite using the same methodology and incorporating additional data, they were still unable to replicate the IQVIA findings. Their conclusion remained unchanged — there was no statistically significant increased risk for NDDs.
Specifically, among 961 children exposed to paternal valproate monotherapy and 1401 exposed to lamotrigine or levetiracetam, there was no significant increase in risk for NDDs (adjusted hazard ratio [aHR], 1.02; 95% CI, 0.67-1.54).
'This finding remained robust across analyses of specific NDDs, analyses of valproate dose, analyses accounting for time trends, analyses allowing for polytherapy, analyses expanding the definition of NDDs, analyses restricted to fathers with epilepsy, and analyses with a restricted exposure window,' Christensen and colleagues reported.
Restricting analyses to fathers with epilepsy of unknown cause yielded a higher risk (aHR, 2.48; 95% CI, 1.13-5.44), but this association was no longer significant in analyses matched on birth year (aHR, 2.33; 95% CI, 1.00-5.44).
Additional sensitivity analyses (restricting exposure window, excluding children with epilepsy or maternal epilepsy, and accounting for polytherapy) consistently showed no elevated risk for NDDs associated with paternal valproate exposure.
'We've examined this issue from many angles and still find no evidence supporting the concern behind EMA's recommendations,' Christensen said in a news release.
Will the EMA Reconsider?
Reached for comment, Aatif Husain, MD, epileptologist, neurologist, and sleep medicine specialist at DukeHealth, Durham, North Carolina, said, 'There seems to be a fair amount of literature' suggesting no increased risk for NDDs in children whose fathers use valproate.
'A recent systematic review that included 10 other studies came to this same conclusion,' said Husain, who wasn't involved in the Danish study.
Taken together, the data 'would probably move EMA to relook at their guidance to see if it needs to be modified,' he said.
Medscape Medical News reached out to the EMA press office for comment and received the following response.
'As with every medicine authorized in the EU, EMA continues monitoring and supervising the safety of these medicines. This includes monitoring information from various sources, such as spontaneous reports, clinical studies, scientific literature, and management of safety signals, which consists of a set of activities to determine whether there are new risks associated with an active substance or a medicine or whether known risks have changed. Should there be any updates, EMA will communicate them via the PRAC Highlights.'
Husain told Medscape Medical News that neither the FDA nor the American Epilepsy Society has issued guidance on valproate use in men 'because the data has not been strong enough.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 hours ago
- Yahoo
Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75
Sir David Nabarro, who was the World Health Organisation's (WHO) special envoy for Covid-19, has died aged 75. The WHO's director-general Dr Tedros Adhanom Ghebreyesus said he was 'deeply shocked and saddened by the passing' of Sir David. London-born Sir David worked at the United Nations for 17 years, expanding nutrition programmes to underdeveloped countries and tackling health crises including outbreaks of malaria, bird flu and Ebola, before leaving in 2017. He was appointed as special envoy on Covid-19 for the WHO in 2020 and appeared on news programmes regularly throughout the pandemic, telling Sky News in June 2021 that humanity was going to have to learn how to 'co-exist' with Covid-19. Sir David was knighted at Buckingham Palace in March 2023 for his outstanding contribution to global health. Dr Tedros wrote on X: 'Deeply shocked and saddened by the passing of our dear friend, colleague and WHO Envoy David Nabarro. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals. 'His work touched and impacted so many lives across the world. 'On behalf of WHO, I'm extending our heartfelt condolences to David's family, friends and colleagues. 'Rest in peace, my dear friend. We will dearly miss your expertise, wisdom and kindness.'
Yahoo
2 hours ago
- Yahoo
Best-ever map of the human genome sheds light on 'jumping genes,' 'junk DNA' and more
When you buy through links on our articles, Future and its syndication partners may earn a commission. Twenty-two years after the completion of the Human Genome Project, scientists have unveiled the most expansive catalog of human genetic variation ever compiled. Across two new papers published Wednesday (July 23) in the journal Nature, scientists sequenced the DNA of 1,084 people around the world. They leveraged recent technological advancements to analyze long stretches of genetic material from each person, stitched those fragments together and compared the resulting genomes in fine detail. The results deepen our understanding of "structural variants" within the human genome. Rather than affecting a single "letter" in DNA's code, such variations affect large chunks of the code — they may be deleted from or added to the genome, or encompass places where the DNA has been flipped around or moved to a different location. The studies have revealed "hidden" features of the human genome that were previously too technologically challenging to study, said Jan Korbel, the interim head of European Molecular Biology Laboratory (EMBL) Heidelberg, who is a co-author of both new papers. For instance, large portions of the genome contain codes that repeat over and over, and these were thought to be nonfunctional. "Some 20 years ago, we thought about this as 'junk DNA' — we gave it a very bad term," Korbel told Live Science. "There's more and more the realization that these sequences are not junk," and the new work sheds light on these long-maligned DNA sequences. Additionally, all of the data generated in the new studies are open access, so others in the field can now take "the findings, some of the tools we've developed and use them for their purposes to understand the genetic basis of disease," Korbel told Live Science. "I thoroughly believe that the advances that we're publishing in Nature today, a subset of these will also make it into diagnostics." Related: People's racial and ethnic identities don't reflect their genetic ancestry Over 1,000 genomes When the first draft of a "complete" human genome was published in 2003, it was actually missing about 15% of its sequence due to technological limitations of the time. In 2013, scientists managed to close that gap by about half. And finally, in 2022, the first "gapless" human genome was published. In 2023, researchers published the first draft of a human pangenome, which incorporated DNA from 47 people around the world, rather than predominantly being based on one person's DNA. And that same year, researchers published the first Y chromosome that had ever been sequenced from end to end, because the previous "gapless" genome was still missing the male sex chromosome. In the past few years, the field has continued to advance, thanks to new technologies and efforts to expand DNA sampling beyond populations of mostly European descent. Those advancements heralded the two papers published in Nature this week. In the first study, researchers sequenced the DNA of 1,019 people representing 26 populations across five continents. To analyze the DNA, the researchers collected "long reads," each composed of tens of thousands of base pairs; one base pair corresponds with one rung in the spiral ladder of a DNA molecule. "With short reads of around 100 base pairs, it is difficult to distinguish between genomic regions that look alike," explained study co-author Jesus Emiliano Sotelo-Fonseca, a doctoral student at the Centre for Genomic Regulation (CGR) in Barcelona, Spain. That's especially true in repetitive regions of the genome. "With longer reads, of around 20k base pairs, assigning each read to a unique position in the genome gets much easier," he told Live Science in an email. More than half of the new genomic variation uncovered in the study was found in those tricky repetitive regions, including in transposons, also known as jumping genes. Transposons can leap to different locations in the genome, copying and pasting their code. Sometimes, depending on where they land, they can destabilize the genome, introduce harmful mutations and contribute to diseases like cancer. "Our study reveals that some of these transposons can hijack regulatory sequences to boost their activity, contributing to understanding the biological mechanisms behind their mutagenicity," or ability to trigger mutations, study co-author Bernardo Rodríguez-Martín, an independent fellow at CGR and a former postdoc in Korbel's EMBL lab, told Live Science in an email. The jumping genes can essentially hitch a ride with certain regulatory molecules — long noncoding RNAs — and use that trick to make far more copies of themselves than they usually would. "That's a very surprising mechanism to us," Korbel said. Related: Scientists just discovered a new way cells control their genes From 95% to 99% The second study featured far fewer genomes — only 65 in total — but sequenced those genomes more comprehensively than the first study did. The first study captured about 95% of each genome analyzed, while the second study generated 99%-complete genomes. "It might sound like a small difference, but it's huge actually from the perspective of the genome scientist," Korbel said. "To get the last few percentages, it's a major achievement." That leap required different sequencing techniques, as well as new analytical approaches. "This project used cutting-edge software to assemble genomes and identify genetic variation, much of which simply did not exist a few years ago," co-author Charles Lee, a professor at the Jackson Laboratory for Genomic Medicine, told Live Science in an email. The sequencing techniques included one that generated long reads with very few errors and one that generated ultralong reads that were slightly more error-prone. At the expense of analyzing fewer genomes, this approach nonetheless enabled the second study to capture stretches of DNA that were totally missed in the first, Rodríguez-Martín said. Those "hidden" regions included the centromeres, important structures at the centers of chromosomes that are key for cell division. As a cell prepares to split, fibers attach to the centromeres and then pull the chromosome in two. The study found that, in about 7% of centromeres, there are likely two places where these fibers can attach, instead of only one. "Could that mean that those chromosomes are more unstable? Because if the spindle [fiber] attaches to two points, it might get confused," Korbel said. That's a purely speculative idea, he added, but it's one that can now be explored. The next step will be to study the effects of these centromere variations experimentally, Lee agreed. Issues with chromosome splitting can lead to various conditions. For example, "Down syndrome is the result of a mistake of chromosome segregation during cell division in meiosis," when cells split to form sperm and eggs, co-author Dr. Miriam Konkel, an assistant professor at the Clemson University Center for Human Genetics, told Live Science in an email. Like the first study, the second study also provided an unprecedented look at jumping genes, cataloging more than 12,900. Beyond cancer, jumping genes can also trigger various genetic diseases by causing mutations, as well as prompt more subtle changes in how genes are switched on and off, Konkel noted. A better understanding of the diversity of jumping genes can help unpack their function in human health and disease. Looking at both studies, scientists can now compare the newly sequenced genomes to other datasets that include both genome and health data, Korbel noted. This would be the first step toward linking the newfound structural variations to tangible health outcomes and, eventually, to incorporating those insights into medical practice. RELATED STORIES —Largest human family tree ever created retraces the history of our species —More than 150 'made-from-scratch' genes are in the human genome. 2 are totally unique to us. —As little as 1.5% of our genome is 'uniquely human' "Certain clinical studies will not be able to ignore these [sequencing] techniques because they will give them higher sensitivity to identify variation," Korbel said. "You don't want to miss variants." There's still more work to be done to improve the genomic data, as well, Lee added. More DNA could be incorporated from underrepresented populations, and the sequencing techniques and software could be further refined to make the process more efficient and accurate. But in the meantime, the pair of new studies marks a major technological feat. "These advanced tools were developed recently to handle the huge amounts of long-read data we are now using for each genome," Lee said. "A few years back, assembling a complete human chromosome from end to end, especially including centromeres, was virtually unattainable because the software and algorithms were not mature yet." Solve the daily Crossword